P21

Also known as: P021, Peptide 021

A CNTF-derived peptide for neurogenesis and cognitive support.

Overview

P21 is a small peptide derived from ciliary neurotrophic factor (CNTF) that promotes neurogenesis and has shown benefits in Alzheimer's disease models.

Mechanism of Action

Stimulates neurogenesis in the dentate gyrus of the hippocampus. Inhibits leukemia inhibitory factor (LIF) signaling to reduce neuroinflammation. Promotes BDNF expression.

Pharmacokinetics

Can be administered intranasally or peripherally with CNS effects. Mechanism of brain penetration under investigation.

Dosing Protocols

Note: These are research protocols from literature. This is not medical advice.

1

Research

Dose

75-150 mcg/kg

Frequency

Once daily

Duration

4-8 weeks

Based on animal studies

Stacking Recommendations

Peptides that may be combined based on complementary mechanisms in research settings.

Rationale: Neurogenesis

Synergy: Multiple pathways for brain health

Research Areas

Alzheimer's DiseaseNeurogenesisCognitive DeclineDepression

Key Research Findings

  • 1Increased hippocampal neurogenesis in aged mice
  • 2Improved memory in Alzheimer's mouse models
  • 3Reduced tau pathology
  • 4Enhanced synaptic plasticity

Side Effects & Contraindications

Reported Side Effects

  • Limited data

Contraindications

  • Unknown

Safety Considerations

Limited human safety data. Preclinical studies suggest good tolerability.

Storage Requirements

Store lyophilized at -20C

Scientific References

Quick Reference

Sequence
Ac-DGGL-Aib-G-DGGL-Aib-G-NH2
Molecular Weight
973 g/mol
Half-Life
Unknown
Bioavailability
Intranasal or SC
Research Stage
preclinical
Administration
Intranasal or subcutaneous